Announces a Record 25 Letters of Authorization to Proceed with
Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types
CULVER CITY, Calif.--(BUSINESS WIRE)--
NantWorks,
the parent organization of NantHealth (NASDAQ: NH) and NantKwest
(NASDAQ: NK) announced today that Dr. Patrick Soon-Shiong (Chairman,
CEO, and Founder) will present the current status of these companies and
the overall ecosystem of NantWorks. Specific details will be presented
regarding the current status of GPS CancerTM, including FDA
filings and seminal patents issued covering tumor-normal analysis of DNA.
In addition, details will be presented regarding the record 25 letters
of authorization covering 12 novel biological molecules tested across 20
tumor types within the NantWorks ecosystem of companies, of which 15
letters of authorization were received in 2017 for natural killer cells
in combination with adenovirus, yeast, super agonist IL-15 and
checkpoint inhibitors. The preliminary results of the first in human and
safety studies of the NANT Cancer Vaccine will be released.
Presentation Time:
Time: January 9, 2018 at 5:00pm Pacific Time.
Location: 36th Annual J.P. Morgan Healthcare Conference -
Elizabethan A/B Breakout: Sussex Room
Both the presentation and question and answer session that follows at
5:00pm will be webcast live at the below links and available for replay
at both NantHealth
and NantKwest.
NantWorks
Presents at the 36th Annual J.P. Morgan Healthcare Conference
NantWorksQ
& A Session at the 36th Annual J.P. Morgan Healthcare
Conference
About NantWorks
NantWorks, LLC, is the umbrella organization for an ecosystem of
companies committed to the convergence of 21st century innovative
platforms to transform how we work, live and play: NantHealth,
NantOmics, NantBioScience, NantCell and its affiliate NantKwest,
NantPharma, NantMobile, NantStudio, NantCapital and NantCloud.
Fact-based and solution driven, each of NantWorks’ division companies
operates at the intersection of innovation and infrastructure.
Founded by Dr. Patrick Soon-Shiong, scientist and inventor of the first
human nanoparticle chemotherapeutic agent Abraxane, the core mission for
NantWorks is convergence: to develop and deliver a diverse range of
technologies that accelerate innovation, broaden the scope of scientific
discovery, enhance ground-breaking research, and improve healthcare
treatment for those in need. NantWorks is building an integrated
fact-based, genomically-informed, personalized approach to the delivery
of care and the development of next generation diagnostics and
therapeutics. For more information, please visit www.nantworks.com
or Dr. Soon-Shiong on Twitter @Dr.PatSoonShiong
About NantHealth, Inc
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissues and integrates
this molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system, which includes its unique
software, middleware and hardware systems infrastructure that collects,
indexes, analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and traditional
sources, continuously improves decision-making and further optimizes our
clinical pathways and decision algorithms over time. For more
information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and inflammatory diseases. NK cells are the body’s
first line of defense due to the innate ability of NK cells to rapidly
identify and destroy cells under stress, such as cancer or
virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to grow
active killer cells as a biological cancer therapy, has been designed to
induce cell death against cancer or infected cells by three different
modes of action: (1) Direct killing using activated NK cells (aNK) that
release toxic granules directly into the cell through cell to cell
contact, (2) Antibody-mediated killing using haNKs, which are NK cells
engineered to incorporate a high affinity receptor that binds to an
administered antibody, enhancing the cancer cell killing effect of that
antibody, and (3) Targeted activated killing using taNKs, which are NK
cells engineered to incorporate chimeric antigen receptors (CARs) to
target tumor-specific antigens found on the surface of cancer cells. Our
aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious “cytokine storms”
reported after T cell therapy. As an “off-the-shelf” therapy,
NantKwest’s NK cells do not rely on a patient’s own often compromised
immune system. In Phase 1 clinical trials in patients with late stage
cancer, NantKwest’s NK cells have been successfully administered as an
outpatient infusion therapy without any reported severe side effects,
even at doses of 10 billion cells.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care. For more
information, please visit www.nantkwest.com.
About NANT Cancer Vaccine
The NANT Cancer Vaccine is the first combination immunotherapy protocol
to orchestrate the delivery of metronomic low dose radiation and
chemotherapy with molecularly informed tumor associated antigen vaccines
and natural killer cells, to activate the innate and adaptive immune
system and to induce immunogenic cell death. By inducing immunogenic
cell death and protecting as well as enhancing the innate and adaptive
immune system, the NANT Cancer Vaccine seeks to attain long-term
sustainable remission of multiple tumor types with lower toxicity and
higher efficacy than current standards of care.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180105005856/en/
NantWorks, LLC
Investor Contact:
David Pyrce
SVP,
Innovation and Investor Relations
Cell: 951-551-0949
david.pyrce@nantkwest.com
or
Media
Contact:
Jen Hodson
Public Relations Director
jhodson@nantworks.com
Source: NantWorks, LLC